Search

Your search keyword '"PETR JANSKY"' showing total 69 results

Search Constraints

Start Over You searched for: Author "PETR JANSKY" Remove constraint Author: "PETR JANSKY"
69 results on '"PETR JANSKY"'

Search Results

1. Impact of patient selection in clinical trials: application of ROCKET AF and ARISTOTLE criteria in GARFIELD-AF

2. Rhythm versus rate control in patients with newly diagnosed atrial fibrillation – Observations from the GARFIELD-AF registry

3. On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease

4. Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF

5. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

6. Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial

7. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

8. 36-month clinical outcomes of patients with venous thromboembolism

9. Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial

10. An evaluation of the effects of the European Commission’s proposals for the Common Consolidated Corporate Tax Base

11. Increasing prevalence of hypertension during long-term follow-up in children with autosomal dominant polycystic kidney disease

12. Is Panama really your tax haven? Secrecy jurisdictions and the countries they harm

13. Multinational corporations and tax havens: evidence from country-by-country reporting

14. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

15. Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin

16. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial

17. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation

18. For a Better GLOBE. METR: A Minimum Effective Tax Rate for Multinationals

20. Lowering cholesterol, blood pressure, or both to prevent cardiovascular events : results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants

21. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation

22. Reduced Cerebrovascular Reserve Capacity as a Biomarker of Microangiopathy in Alzheimer’s Disease and Mild Cognitive Impairment

23. Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease

24. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

25. Design and baseline characteristics of participants in the <scp>R</scp> esearching cardiovascular <scp>E</scp> vents with a <scp>W</scp> eekly <scp>IN</scp> cretin in <scp>D</scp> iabetes ( <scp>REWIND</scp> ) trial on the cardiovascular effects of dulaglutide

26. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis

27. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

28. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

29. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients

30. Estimating Illicit Financial Flows : A Critical Guide to the Data, Methodologies, and Findings

31. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study

32. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease

33. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease

34. 360Role of cardioversion in the management of non-valvular atrial fibrillation: insights from the GARFIELD-AF registry

35. Financial Secrecy Affecting the European Union: Patterns Across Member States, and What to Do About It

36. Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention : An Analysis of the HOPE-3 Trial

37. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE) : an international, randomised, placebo-controlled trial

38. Rivaroxaban with or without aspirin in patients with stable coronary artery disease : an international, randomised, double-blind, placebo-controlled trial

39. Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome

40. Warfarin loading dose guided by pharmacogenetics is effective and safe in cardioembolic stroke patients - a randomized, prospective study

41. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide

42. Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin

43. Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries

44. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial

45. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

46. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy

47. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease

48. Tratamiento prehospitalario de los pacientes con IAMCEST. Una declaración científica del Working Group Acute Cardiac Care de la European Society of Cardiology

49. Pre-hospital treatment of STEMI patients. A scientific statement of the Working Group Acute Cardiac Care of the European Society of Cardiology

50. The incidence, treatment strategies and outcomes of acute coronary syndromes in the 'reperfusion network' of different hospital types in the Czech Republic: Results of the Czech evaluation of acute coronary syndromes in hospitalized patients (CZECH) registry

Catalog

Books, media, physical & digital resources